Table 1 Immune checkpoints, their ligands distribution and antibody
From: The importance of N6-methyladenosine modification in tumor immunity and immunotherapy
Immune checkpoint | Ligand | Distribution of ligand | Antibody | Antibody type | Cancer |
|---|---|---|---|---|---|
CTLA-4 | CD80(B7-1) CD86(B7-2) | APCs | Ipilimumab | Human IgG1 | Melanoma |
PD-1 | PD-L1(B7-H1) PD-L2(B7-DC) | Hematopoietic cells Non-hematopoietic cells Tumor cells | Pembrolizumab Nivolumab Atezolizumab | Human IgG4 Human IgG4 Human IgG1 | Melanoma NSCLC |
LAG-3 | MHC-II Galectin-3 LSECtin FGL-1 | APCs Tumor cells | GSK2831781 | Human IgG | Melanoma Colon adenocarcinoma Ovarian cancer |
Tim3 | Galectin-9 Phosphatidylserine CEACAM1 HMGB1 | Hematopoietic cells Apoptotic cells Tumor cells | TSR-022 LY3321367 MBG453 | Human IgG4 Human IgG1 Human IgG4 | Liver cancer Solid tumor AML |
TIGIT | CD155(PVR) CD112(PVRL2) | APCs, T cells Non-hematopoietic cells, Tumor cells | Tiragolumab AB-154 BMS-986,207 | Human IgG1 Human IgG1 Human IgG1 | NSCLC Solid tumor |